Expanded Access to Veliparib
Status: NO_LONGER_AVAILABLE
Study type: EXPANDED_ACCESS
Conditions: Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound|Triple Negative Breast Cancer (TNBC)|High Grade Serous Ovarian Cancer|Patients Requiring Veliparib Suspension Formulation
Interventions: DRUG: Veliparib
Sponsor: AbbVie